Chemiluminescent immunoassay (CLIA) is a quantitative detection technology that applies chemiluminescent technology to the immune recognition reaction. The basic idea is to label the chemiluminescent substance on the antigen or antibody, and after the specific binding with the corresponding antibody or antigen in the sample to form an immune complex. Then, by adding an oxidant or luminescent substrate, a luminescent reaction is induced, and a detectable light signal is generated. Creative Diagnostics has rich technical accumulation in this field and can provide customers with personalized chemiluminescent immunoassay solutions. We mainly develop and manufacture highly sensitive and accurate detection products. The products are commonly used in basic research, clinical diagnosis and industrial testing, and can fully meet the detection needs in different application scenarios.
CLIA offers several advantages over traditional enzyme-linked immunosorbent assays (ELISA). First, CLIA systems usually have higher sensitivity in picogram (sometimes in femtogram) level, which is sufficient for detecting very low concentrations of an analyte. Second, the chemiluminescent reaction is rapid and does not require an external light source. This reduces the background signal and improves the signal to noise ratio. Third, the CLIA platforms can be easily automated. This has made them suitable for high throughput screening (HTS) in clinical laboratories.
There are two main formats of CLIA: direct and indirect. In direct CLIA, the chemiluminescent label is directly attached to the antibody or antigen. By contrast, in indirect CLIA the label is carried by a secondary antibody, which binds to the primary antibody or antigen in the immunoassay complex. To date, CLIA has been increasingly used for the diagnosis of infectious diseases, as well as of cancer markers, cardiac markers, thyroid function, and others. The assay's speed, sensitivity and flexibility have continued to render it an important technique in the practice of modern analytical and diagnostic science.
ADVIA Centaur XP
Synergy Neo2
UniCel DxI Series
As a trusted developer and supplier of chemiluminescent immunoassay (CLIA), Creative Diagnostics provides customized solutions for clinical and research-level rapid diagnostic applications with decades of industry experience. We have technical capabilities covering the entire process of chemiluminescent marker screening and optimization, antigen-antibody coupling technology, solid phase carrier processing, and sensitive signal enhancement system construction, ensuring efficient support at every stage of the development stage. Our expertise enables us to provide highly sensitive and specific chemiluminescent detection solutions for a variety of target analytes. We provide:
To meet the needs of researchers in rapid diagnostic testing, Creative Diagnostics offers customized and professional Chemiluminescent Immunoassay (CLIA) Development services. Utilizing advanced chemiluminescence technologies and innovative assay design strategies, we ensure that the assays we develop are highly sensitive, specific, and reliable. Our services include:
Support Supports automated immunoassay analyzer or microplate chemiluminescence detection system
Methodology development: sandwich method, competitive method, indirect method, etc.
Standard curve drawing, sensitivity/specificity analysis
Clarify the detection target and sample type, and evaluate the feasibility of the project.
Label antibodies to ensure signal strength and specificity.
Design and assemble immunoassay components.
Optimize conditions and verify sensitivity and specificity.
Expand production, provide technical support and delivery.
Creative Diagnostics validated the minimum detection limit (LOD, unit: pg/mL) of four mainstream immunoassay methods on the detection of the same target analyte. The result found that CLIA had the best detection sensitivity, with LOD as low as only 0.2 pg/mL, far better than ELISA, FIA and RIA. This indicates that CLIA has obvious application advantages in high-sensitivity detection scenarios.
Chemiluminescent immunoassay is an analytical method with high sensitivity, based on the combination of immune reaction and chemiluminescence technology. It is used to quantitatively detect specific antigens or antibodies in body fluids, and is a commonly used clinical diagnostic and research method.
Typically, it covers the entire process of antibody labeling, reagent design, detection condition optimization, verification of sensitivity and specificity, as well as large-scale production and technical support.
The development cycle varies with the complexity of the project, usually several weeks to several months, and the time will be adjusted according to the detection target and sample type.
The high sensitivity and specificity of the detection are ensured by optimizing the antibody coupling method, selecting the appropriate chemiluminescent substrate, and a strict verification process.
Yes, the chemiluminescent immunoassay development service can customize detection schemes suitable for different sample types such as serum, plasma, urine, saliva, etc. according to customer needs.
To use our chemiluminescent immunoassay development services, please contact Creative Diagnostics, your expert immunology service provider. From research-scale chemiluminescent immunoassay development to industrial scale-up, our team is ready to support your R&D innovation.
